Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0ABCGI |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-5T4 antibody |
|||||
| Antigen Name | Trophoblast glycoprotein (TPBG) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYMHWVRQAPGQGLEWMGRVSPNNGATNTN
QKFKDRVTMTRDTSISTAYMELRSLRSEDTAVYYCARSTMITSYYFDYWGQGTLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSEVQLLESGGGLVQPGG SLRLSCAASGFDFSRYWMTWVRQAPGKGLEWVEINPDSRTINYTPSLKDRFTISRDNAKN TLYLQMNSLRAEDTAVYYCARPDHDYN PYYFNYWGQGTTVTVSSGGGGSGGGGSGGGGS GGGGSDIVLTQSPASLAVSLGQRATISCRPSQSVSTSSNSYIHWYQQKPGQPPKLLIKYA SNLESGVPARFSGSGSGTDFTLTISPVEAEDATYYCQQSWEIPLTFGCGTKLEIK Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPSSLSASVGDRVTITCKASQSVTDVAWYQQKPGQAPKLLIYFASDRYTGVPDR
FSGSGSGTDFTLTISSLQAEDVAVYYCQQDYSSPPTFGGGTKLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
JK06 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key eligibility: Adults (≥18) with advanced/metastatic solid tumors (ECOG ≤1, measurable disease per RECIST 1.1). Major exclusions: active/unstable CNS metastases, recent major surgery (6 weeks), cardiovascular events (6 months), grade ≥2 neuropathy, live vaccinations (4 weeks), or hypersensitivity to JK06 components. Requires archival tumor samples and acceptable organ function (ANC ≥1,500/uL, platelets ≥100,000, bilirubin ≤1.5×ULN).
Click to Show/Hide
|
||||
| Administration Dosage |
Escalating repeated doses of JK06 administered intravenously. A cycle of treatment is defined as 21 days.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06667960 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer
|
||||
| Primary Endpoint |
Primary objectives assess safety through DLT incidence (first 21 days), MTD/RP2D determination (up to 14 months), and treatment-emergent AE/SAE monitoring (treatment period through 28 days post-last dose) in advanced solid tumor patients receiving JK06.
|
||||
| Other Endpoint |
Secondary endpoints evaluate PK parameters (Cmax, AUC), immunogenicity (ADA levels), and efficacy measures (ORR/DCR by RECIST v1.1, PFS) through 104 weeks of treatment follow-up.
|
||||